跳至主要内容
临床试验/NCT01024712
NCT01024712Unknown2 期

Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial

Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2009年5月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
26
试验地点
2
主要终点
Overall-response rate

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel and carboplatin together with gefitinib may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving paclitaxel and carboplatin together with gefitinib and to see how well it works in treating patients with Stage IIIB or stage IV non-small cell lung cancer.

详细描述

OBJECTIVES:

Primary

  • To determine the efficacy, in terms of overall response, and safety of paclitaxel and carboplatin in combination with intermittent gefitinib in patients with advanced nonsquamous non-small cell lung cancer.

Secondary

  • Determine the disease-control rate in patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.
  • Determine the progression-free and overall survival of patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall-response rate

次要结局

  • Disease-control rate
  • Safety
  • Quality of life
  • Progression-free survival
  • Overall survival

研究者

研究点 (2)

Loading locations...

相似试验